Nanohydroxyapatite and its composite scaffold for bone tissue engineering application: a systematic review
Abstract
Osteoporosis, osteomyelitis disease, bone tumors, bacterial infections, and accidents are posing a great challenge in the orthopedic field. For decades, autograft and allograft transplant techniques have been considered gold-standard treatments for bone problems. Given these limitations and increased medical demand for bone substitute material, the orthopedic field has sparked rapid interest in building safe and biocompatible materials. In search of alternatives, biomaterials such as bioactive glasses, hydroxyapatite (HAp), calcium silicate, β-tricalcium phosphate, etc., offer new insights for bone regeneration. In particular, HAp [Ca10(PO4)6(OH)2] has drawn considerable attention because the bone has HAp as a major inorganic component. In addition, HAp has bioactivity, biocompatibility, and osteointegration properties. Further, to enhance the biological properties of the HAp, it has been modified to a nanoscale level and named nanohydroxyapatite (nHAp). The nHAp has a larger surface area, which helps to facilitate drug loading, gene delivery, and fast recovery of injured bone. Thus, the present review spotlights a brief introduction to HAp and nHAp, their history, basic properties, synthesis methods, and composites with metals, polymers, ceramics, growth factors, etc., for bone tissue engineering applications.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.